Introduction
Kallikreins are a family of serine protease enzymes with diverse physiological roles. They have been linked to cancer development and show promise as potential biomarkers for the disease. KLK1 is a member of the kallikrein subfamily, consisting of fifteen members clustered on chromosome 19. A key function of KLK1 is the release of the vasoactive peptide, Lys-bradykinin, from low molecular weight kininogen, a function conserved across species. Also known as Kallidinogenase, Kininogenase, or Kininogenin, human Kallikrein-1 is an active enzyme found in saliva, pancreatic juices, and urine. It catalyzes the breakdown of bradykininogen to bradykinin. Human and porcine-derived Kallikrein-1 have a history of medicinal use, primarily for mild to moderate hypertension and treating blockages in the brain and surrounding blood vessels. KLK1 exhibits both trypsin- and chymotrypsin-like activities, showing a preference for Tyr/Arg at the P1 site, Ser/Arg at P1', and Phe/Leu at P2. Studies have shown a significant association between rs5517 in the KLK1 gene and hypertension in a Chinese Han population. KLK1 expression, observed to be de novo in endothelial cells, plays a role in relaxing human umbilical veins. The K allele of the KLK1 promoter and the TT genotype of TGF-beta1, along with KLK1 -130 GN and -128 G-C, have been identified as genetic susceptibility factors for progressive renal decline in Taiwanese children with primary vesicoureteric reflux. Interestingly, KLK1 induction in carotid arteriosclerosis does not activate the kallikrein-kinins pathway. Transgenic rats overexpressing KLK1 exhibit impaired renal response to acute volume expansion. Endothelial cells synthesize and release active KLK1, which plays a crucial role in maintaining circulatory homeostasis. KLK1 also participates in epidermal desquamation by cleaving desmoglein 1, a process regulated by the lympho-epithelial Kazal-type-related inhibitor (LEKTI).
Description
Recombinant human Kallikrein-1, produced in E. coli, is a single, non-glycosylated polypeptide chain. It consists of 259 amino acids (residues 25-262) and has a molecular weight of 28.7kDa. The KLK1 protein includes a 21 amino acid His-tag at the N-terminus and is purified using proprietary chromatographic methods.
Physical Appearance
A clear solution that has been sterilized by filtration.
Formulation
The KLK1 solution is provided at a concentration of 0.25mg/ml and contains 20mM Tris-HCl buffer (pH 8.0), 0.15M NaCl, 10% glycerol, and 1mM DTT.
Stability
For short-term storage (up to 2-4 weeks), store the vial at 4°C. For extended storage, freeze the product at -20°C. To enhance long-term stability, consider adding a carrier protein like HSA or BSA (0.1%). Minimize freeze-thaw cycles to maintain product integrity.
Purity
The purity of KLK1 is determined to be greater than 90.0% using SDS-PAGE analysis.
Synonyms
KLK1, KLK-1, HK1, HK-1, KLKR, KLK6, Tissue Kallikrein, hKLK1, EC 3.4.21.35, Kidney/pancreas/salivary gland kallikrein, Kallikrein-1.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MIVGGWECEQ HSQPWQAALY HFSTFQCGGI LVHRQWVLTA AHCISDNYQL WLGRHNLFDD ENTAQFVHVS ESFPHPGFNM SLLENHTRQA DEDYSHDLML LRLTEPADTI TDAVKVVELP TQEPEVGSTC LASGWGSIEP ENFSFPDDLQ CVDLKILPND ECKKVHVQKV TDFMLCVGHL EGGKDTCVGD SGGPLMCDGV LQGVTSWGYV PCGTPNKPSV AVRVLSYVKW IEDTIAENS.
